Search

LONDON, ON- A recently published preclinical study by researchers at Lawson Health Research Institute and Western University’s Schulich School of Medicine & Dentistry show that vaping may negatively affect pulmonary surfactant in the lungs.

Surfactant, which is made of lipids and proteins, is a critical layer in the lungs that allows people to breathe with minimal effort by reducing surface tension. Without surfactant, it would take more effort to breathe and a person would need mechanical help to do so.

“Vaping continues to be popular but not much is known about what happens with the aerosol when it enters the lungs,” says Dr. Ruud Veldhuizen, Lawson Scientist and Professor at Schulich Medicine & Dentistry. “We realized that the first thing the vapor aerosol comes in contact with in the lungs is pulmonary surfactant, which is an area our team specializes in.”

The research team was able to study the effects by placing a film of surfactant inside a syringe and, then using a vaping device to push aerosol into the syringe. This allowed the vapor to directly interact with the surfactant. The researchers then mimicked inhaling and exhaling vapor into the syringe 30 times to resemble a standard vaping session.

“In particular we were looking at the surface tension in the surfactant,” explains Emma Graham, Master’s student at Schulich Medicine & Dentistry. “After vaping, we saw high surface tension which suggests the surfactant would not be as effective at supporting proper lung functioning.”

The team also examined different vaping devices, flavours, additives and nicotine to see if there were any difference in effects.

“Nicotine didn’t have any worse effects on surface tension of surfactant compared to other e-liquids, but some flavourings like menthol e-liquid did,” says Graham.

While his team intends to study this further, Veldhuizen says these findings could provide an indication as to why people that vape have a susceptibility to develop lung injury, including those with respiratory viruses such as COVID-19.

“We would like to get this information out there so that people know vaping may be damaging to the lungs,” says Veldhuizen. “As a next step, we hope to further investigate the effects of vaping on the lungs and how we can treat resulting injury.”

The study has been published in the PLOS ONE Journal.  These findings build on a body of research about the impacts of vaping through Lawson and Schulich Medicine & Dentistry. Our researchers were the first in the world to report on a potential new type of vaping-related injury in 2019.

London - In a national multicentre study, scientists at Lawson Health Research Institute and Western University are working to create rare isotopes that will be used as an important tool to help treat cancer.

Currently, radiation therapy is a staple in cancer treatment, with approximately 50 per cent of cancer patients receiving radiation at some point in their cancer journey. Although a very effective tool, traditional radiation therapies rely on intense beams of energy. These beams can kill cancer cells, but their use is limited to select locations, making them less suited for difficult-to-treat metastatic cancers that have spread to multiple sites.

“Cancer treatment has evolved over the years with targeted drugs that go straight to the cancer and advanced radiation therapy. However, radiation comes from an external source that can damage other areas in the body,” says Dr. Len Luyt, Lawson Scientist and Professor at Western. “We are now working to advance treatment further by combining radiation and targeted drug therapy.”

The therapies work like a homing device — using specially designed molecules to seek out and deliver radioactive isotopes directly to cancer cells, wherever they might be in the body.

The multidisciplinary research team involves researchers at Lawson, Western University, University of British Columbia, BC Cancer, TRIUMF, Simon Fraser University, Université Laval, Université de Sherbrooke, University of Toronto and University of Alberta.

“This is the holy grail of cancer treatment. These disease-targeting molecules circulate throughout the body, binding tightly to cancer cells in order to eliminate them with a highly localized blast of energy,” explains principal investigator Dr. François Bénard, Professor of Radiology and Associate Dean at UBC’s Faculty of Medicine, and Senior Executive Director of the BC Cancer Research Institute.

The London, Ontario team will focus on developing the radio pharmaceuticals at labs in the London Regional Cancer Program at LHSC, the Cyclotron located at St. Joseph’s Health Care London, and at Western. 

“The radio pharmaceuticals we are designing will be very specific to certain receptor proteins that are on cancer cells and not elsewhere on the body. This allows us to bring the isotopes to the cancer cells and clear it from the body so you have less side effects in other areas,” says Dr. Luyt. “This approach is showing promise in prostate cancer and now this team-based approach is looking at targeting any metastatic cancer.”

This collaborative research project has received $23.7 million in federal funding through the New Frontiers Research Fund (NFRF) over six years.

“We will establish Canada as a world leader in the field of nuclear medicine and ensure Canadian patients are the ones who benefit,” adds Dr. Bénard. “By developing these medicines in Canada and bringing them into local clinical trials, we will ensure Canadians have access to innovative cancer treatments sooner.”

The team hopes to bring multiple drug candidates into clinical trials in the coming years with the ultimate goal of developing an effective treatment for metastatic cancer patients. 

Scientists examining microbiome to improve cancer therapies

MEDIA RELEASE 
For Immediate Release 

LONDON, ON- Pancreatic cancer is an aggressive disease that affects up to six-thousand Canadians a year and is the third leading cause of cancer deaths. In a new study a multidisciplinary team of scientists at Lawson Health Research Institute are examining the microbiome in the gut, as a possible gateway to improving treatment outcomes.

“Pancreatic cancer is very hard to treat, partially because when it’s detected, the cancer is usually in a later stage and spreads very quickly,” explains Dr. John Lenehan, Medical Oncologist at London Health Sciences Centre’s London Regional Cancer Program (LRCP) and Associate Scientist at Lawson. “Our best chemotherapy treatments for the average patient, will give them a little less than a year to live.”

With the goal of improving treatments for these patients the research team led by Dr. Saman Maleki, Scientist at Lawson, is studying whether changing the gut microbiome can result in better response to cancer treatments. 

“We know that the microbiome plays an important role in patients’ response to various forms of systemic treatments such as immunotherapy and chemotherapy for different cancers,” says Dr. Maleki.

This unique study will happen in three stages. The first stage is an observational study to examine fecal samples of 52 patients at LRCP with advanced pancreatic cancer. The second stage will focus on using the samples from these patients in preclinical models to test new combinations of treatments. The final stage of the study will focus on intervention through human clinical trials by modifying a patient’s microbiome with something called a fecal transplant prior to treatment.

“The microbiome is involved in many aspects of cancer development and these organisms aren’t just living in the gut but also within the tumor,” says Dr. Michael Silverman, Lawson Scientist and Chair/Chief of Infectious Diseases at LHSC and St. Joseph’s Health Care London. “We believe that by giving people a fecal transplant, we can change the bacteria that live within the tumor and gut and then optimize the immune response to both the tumour and to treatment, with the goal of improving patient outcomes.”

Fecal transplants involve collecting stool from a healthy donor, preparing it in a lab and safely transplanting it to the patient, in this case with a capsule. The goal is to transplant the donor’s microbiome so that healthy bacteria will colonize in the patient’s gut.

“If you think of microbiome, each bacterium is like a little factory and all together they are a giant factory within us producing things we need,” explains Dr. Jeremy Burton, Lawson Scientist who specializes in human microbiome research. “Over time, a person’s diet, medications, and lifestyle can change the microbiome and it can have a big impact to the rest of our body.” 

The research team was recently awarded a $450,000 Catalyst 2021 grant from the Weston Family Foundation to conduct this study, which is the first in the world focusing on prospectively modifying the microbiome in pancreatic cancer patients for treatments and outcomes.

“We normally don’t see this in one study where we go through the full spectrum of learning from patients, to looking at treatments, and then moving to a final intervention stage,” explains Dr. Maleki. “This has not been tried in pancreatic cancer before, but we think leveraging the microbiome and improving the immune response can potentially move the needle in this patient population.”

The team is recruiting both pancreatic cancer patients, as well as healthy volunteers for fecal transplant samples. Those interested in helping with fecal transplant donations can contact Dr. Seema Parvathy at 519-646-6100 ext. 61726 or email seemanair@@email

-30-